Dr.ObesityMed said:
CRP reduction on cardiovascular risk — this is the lab result that excites me most: Baseline hsCRP: 10.0 mg/L (high cardiovascular risk) Month 6…
SUSTAIN-6 was the first CVOT to show cardiovascular benefit with semaglutide, relevant to cardiovascular risk. In 3,297 T2DM patients with high CV risk: MACE HR 0.74 (95% CI 0.58-0.95, p=0.02)[1].
Notable: the retinopathy signal in SUSTAIN-6 (HR 1.76) was subsequently attributed to rapid A1C reduction in patients with pre-existing retinopathy — not a direct drug effect. This has been confirmed in longer-term follow-up studies.
References:
[1] Marso SP, et al. N Engl J Med. 2016;375(19):1834-1844.